Poxel

POXEL

FR0012432516

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:26 2024-04-26 am EDT			5-day change	1st Jan Change
0.673 ^EUR	+1.97%		+2.91%	+22.14%

Apr. 11	Poxel: CDC falls below the 10% threshold	CF
Feb. 15	Poxel S.A. Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Presentation Operator MessageOperator (Operator)Welcome to the Poxel KOL Investor Event Confer...

This article is reserved for subscribers

Signed up already?

Not subscribed yet?

Latest news about Poxel

Poxel: CDC falls below the 10% threshold	Apr. 11	CF
Poxel S.A. Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
Poxel: share price rises, boosted by savings plan	Dec. 22	CF
Global markets live: Coty, Sanofi, Ford, Spotify, Tesla...	23-09-26
Transcript : Poxel S.A., H1 2023 Earnings Call, Sep 26, 2023	23-09-26
Poxel: losses widen, share price falls	23-09-26	CF
Poxel S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
Poxel: financing secured until mid-2025	23-08-31	CF
Poxel: Bpifrance Investissement down to less than 5%.	23-08-25	CF
Poxel: published cash position for Q1 2023	23-05-19	CF
Global markets live: Burberry, Cisco, Walmart, Alibaba, Charles Schwab...	23-05-18
Poxel S.A. Auditor Raises 'Going Concern' Doubt	23-05-02	CI
Poxel: EPIC Bpifrance below 15% threshold	23-04-11	CF
Poxel: CDC falls below 15% of capital and voting rights	23-04-05	CF
POXEL : Degroof Petercam reduces its target	23-03-28	CF
Transcript : Poxel S.A., 2022 Earnings Call, Mar 23, 2023	23-03-23
Poxel: financial visibility extended to 2025	23-03-23	CF
Poxel S.A. announced that it has received ?3.5 million in funding from Iriso Electronics Co., Ltd.	23-03-22	CI
Poxel: publication of annual results postponed	23-03-22	CF
Poxel: publication in the Journal of Hepatology	23-03-07	CF
Poxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology	23-03-07	CI
Poxel Announces Publication in Kidney International of Pxl770 Preclinical Results in Autosomal Dominant Polycystic Kidney Disease	23-03-01	CI
Poxel S.A. Reports Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-15	CI
Poxel: share price rises following orphan drug designation	23-01-25	CF
Poxel S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-01-11	CI

Poxel is a biopharmaceutical company specializing in developing innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare diseases. TWYMEEG® (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan for the treatment of type 2 diabetes. For the treatment of NASH, the PXL065 met its primary endpoint in a streamlined Phase II trial, and PXL770 has completed a Phase IIa proof-of-concept study by reaching its objectives. In adrenoleukodystrophy (ALD), a rare inherited metabolic disease, the company intends to initiate Phase IIa proof-of-concept studies with the PXL065 and the PXL770 in patients with adrenomyeloneuropathy (AMN).

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - Q1 2024 Sales and Revenue Release

More about the company

	1st Jan change	Capi.
POXEL	+22.14%	27.4M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.71B
ARGENX SE	+1.69%	22.02B
BIONTECH SE	-17.37%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-41.01%	16.21B
BEIGENE, LTD.	-14.85%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.86B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.04B